How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Vikki Velasquez is a researcher and writer who has managed, coordinated, and directed various community and nonprofit organizations. She has conducted in-depth research on social and economic issues ...

Gordon Scott has been an active investor and technical analyst for 20+ years. He is a Chartered Market Technician (CMT). Yarilet Perez is an experienced multimedia journalist and fact-checker with a ...

The people building AI fear progress will soon accelerate violently. Should we believe them?

On Tuesday, the AI company Recursive Superintelligence announced a $410 million compute deal with Amazon Web Services. The company, which emerged from stealth in May with $650 million in funding, is ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Sarah Bradley is a writer with six years of experience creating personal essays, reported features, and content related to health and parenting topics. Susan Bard, MD, is a board-certified general and ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...